Urgent Product Defect Correction: Medtronic CGM Systems

Published: 15 March, 2021

TGA Ref: RC-2021-RN-00677-1

Medtronic Australasia Pty Ltd recently became aware that a specific medication, hydroxyurea, falsely increases glucose readings on Medtronic CGM systems. This may result in failure to treat hypoglycaemia from missed low sensor glucose readings or by causing other errors in diabetes management decisions.

Medtronic Australasia Pty Ltd has provided additional information about this Defect Correction notice here.

Diabetes Australia acknowledges Aboriginal and Torres Strait Islander peoples as the Traditional Owners and Custodians of this Country. We recognise their connection to land, waters, winds and culture. We pay the upmost respect to them, their cultures and to their Elders, past and present. We are committed to improving health outcomes for all Aboriginal and Torres Strait Islander people affected by diabetes and those at risk.

Learn about the artwork